Yeztugo Injection Faces Insurance Hurdles Despite Initial Uptake
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 2 days ago
0mins
Should l Buy GILD?
Source: Newsfilter
- Market Acceptance: Since its June launch, Yeztugo has seen usage climb to nearly 75 patients, significantly lower than the expected 700 PrEP patients, indicating a lack of interest among patients that hampers Gilead's market expansion strategy.
- Insurance Coverage Issues: While Gilead claims over 90% of insurers cover Yeztugo, many patients face injection costs exceeding $14,000 and insurance denials, leading them to opt for cheaper daily medications, which impacts sales growth.
- Prescription Data Comparison: In the first quarter, over 9,000 prescriptions were written for Yeztugo, compared to 461,000 for Descovy, highlighting a preference for traditional daily medications that limits Yeztugo's market share.
- Future Sales Expectations: Analysts estimate that Yeztugo's annual sales could exceed $5 billion by 2032, although current insurance coverage and patient acceptance issues may hinder the achievement of this target.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy GILD?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on GILD
Wall Street analysts forecast GILD stock price to rise
19 Analyst Rating
16 Buy
3 Hold
0 Sell
Strong Buy
Current: 136.300
Low
105.00
Averages
137.88
High
154.00
Current: 136.300
Low
105.00
Averages
137.88
High
154.00
About GILD
Gilead Sciences, Inc. is a biopharmaceutical company. It is engaged in advancing medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis, COVID-19, cancer, and inflammation. It is focused on discovering, developing, and delivering medicines to address unmet medical needs in virology, oncology, and other therapeutic areas. Its portfolio of marketed products includes AmBisome, Atripla, Biktarvy, Cayston, Complera, Descovy, Descovy for PrEP, Emtriva, Epclusa, Eviplera, Genvoya, Harvoni, Hepcludex, Hepsera, Jyseleca, Letairis, Livdelzi/Lyvdelzi, Odefsey, Sovaldi, Stribild, Sunlenca, Tecartus, Trodelvy, Truvada for PrEP, and others. It also sells and distributes authorized generic versions of Epclusa and Harvoni in the United States through its subsidiary, Asegua Therapeutics LLC. It has control on anitocabtagene autoleucel (anito cel), an investigational BCMA-directed CAR T cell therapy for multiple myeloma. It operates in over 35 countries worldwide.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Gilead Sciences Set to Release Q1 Earnings on May 7
- Earnings Announcement: Gilead Sciences is set to announce its Q1 2023 earnings on May 7, with consensus EPS estimates at $1.91, reflecting a 5.5% year-over-year increase, and revenue expectations at $6.92 billion, up 3.7%, indicating stable performance in the biopharma sector.
- Performance Outlook: Despite a double beat in the previous quarter, Gilead's 2026 non-GAAP EPS guidance midpoint of $8.65 falls below consensus, highlighting cautious market sentiment regarding its future growth potential.
- Market Analysis: Analyst Edmund Ingham notes that Gilead's heavy reliance on its HIV division, coupled with skepticism surrounding its recent $11 billion M&A spree, suggests that Q1 earnings may be underwhelming, with sluggish growth anticipated.
- Estimate Revisions: Over the past three months, EPS estimates have seen four upward revisions and five downward adjustments, while revenue estimates have experienced two upward and five downward revisions, reflecting market divergence and uncertainty regarding Gilead's future performance.
See More
Gilead Sciences to Release Q1 Earnings on May 7
- Earnings Release Announcement: Gilead Sciences is set to announce its Q1 2023 earnings on May 7, with analysts forecasting an EPS of $1.91 and revenue of $6.92 billion, reflecting a cautiously optimistic market outlook.
- Stock Performance: As of April 29, Gilead's stock closed at $136.30, indicating that investors are adopting a wait-and-see approach ahead of the earnings report, which may influence short-term market volatility.
- Market Expectation Analysis: Analysts' earnings expectations demonstrate confidence in Gilead's product pipeline and market demand, particularly in the increasingly competitive biopharmaceutical sector, where exceeding expectations could bolster the stock price.
- Financial Health Outlook: If actual results meet or exceed expectations, it could enhance investor confidence and further solidify the company's market position in the biopharmaceutical industry; conversely, disappointing results may lead to a decline in stock price.
See More
California Supreme Court to Hear Gilead Drug Liability Case
- Legal Responsibility Review: The California Supreme Court is set to hear Gilead's appeal regarding whether drug manufacturers are obligated to continue developing allegedly safer alternatives, a decision that could reshape product liability law and impact innovation in the pharmaceutical industry.
- Patient Lawsuit Background: Approximately 24,000 HIV patients have sued Gilead, alleging that the company halted the development of TAF, a drug with fewer side effects, to protect the market for TDF, potentially increasing health risks for patients.
- Debate on Innovation and Liability: In its appeal, Gilead argues that allowing patients to sue would stifle innovation, as drugmakers could face liability for failing to commercialize new drugs, which may ultimately reduce the development of new treatments.
- Profit vs. Ethical Considerations: Patients contend that Gilead made billions in additional profits from TDF after its patent expired in 2017, questioning the reasonableness of the decision to delay TAF's commercialization and highlighting the ethical responsibilities of pharmaceutical companies in balancing profit and patient health.
See More
China Emerges as a Leader in Global Pharmaceutical Innovation
- Earnings Beat: Waters reported adjusted earnings per share of $2.70, exceeding estimates of $2.31, with revenue of $1.27 billion surpassing the $1.20 billion forecast, indicating strong performance driven by the pharmaceutical segment, particularly in China.
- China's Market Growth: The pharmaceutical segment grew 14%, with China leading at over 50% growth, while India and Japan saw low-teens growth, highlighting China's rapid emergence as a key player in global pharmaceutical innovation and market expansion.
- Innovation-Driven Transformation: Despite a decline in China's generic drug market due to price restrictions, the development of innovative drugs is reshaping the landscape, with contract manufacturers rapidly scaling up to manage the entire process from discovery to development, aiming to create entities akin to Pfizer or AstraZeneca.
- Regional Performance: Asia's growth was nearly 30%, while the Americas and Europe achieved high single-digit growth, reflecting a diversified development trend in the global pharmaceutical market, with Waters' success underscoring the effectiveness of this strategic approach.
See More
Yeztugo Injection Faces Insurance Hurdles Despite Initial Uptake
- Market Acceptance: Since its June launch, Yeztugo has seen usage climb to nearly 75 patients, significantly lower than the expected 700 PrEP patients, indicating a lack of interest among patients that hampers Gilead's market expansion strategy.
- Insurance Coverage Issues: While Gilead claims over 90% of insurers cover Yeztugo, many patients face injection costs exceeding $14,000 and insurance denials, leading them to opt for cheaper daily medications, which impacts sales growth.
- Prescription Data Comparison: In the first quarter, over 9,000 prescriptions were written for Yeztugo, compared to 461,000 for Descovy, highlighting a preference for traditional daily medications that limits Yeztugo's market share.
- Future Sales Expectations: Analysts estimate that Yeztugo's annual sales could exceed $5 billion by 2032, although current insurance coverage and patient acceptance issues may hinder the achievement of this target.
See More
Analysis of Upcoming U.S. Jobs Report Outlook
- Job Market Expectations: According to FactSet consensus estimates, the U.S. is expected to add only 50,000 jobs in April, significantly lower than March's 178,000, indicating signs of economic slowdown that could impact investor confidence.
- Unemployment Rate Stability: The unemployment rate is anticipated to remain steady at 4.3%, suggesting that despite the decrease in job additions, the labor market remains relatively stable, potentially alleviating fears of an economic downturn.
- GDP Growth Situation: The U.S. GDP grew at a seasonally adjusted annualized rate of 2% in the first quarter, higher than the fourth quarter's 0.5% but below the 2.2% estimate, reflecting economic sluggishness that may influence future monetary policy decisions.
- Market Volatility: Despite a strong performance in April, with the S&P 500 and Nasdaq hitting record highs, investors should remain cautious of the upcoming
See More
Gilead Sciences Set to Release Q1 Earnings on May 7
- Earnings Announcement: Gilead Sciences is set to announce its Q1 2023 earnings on May 7, with consensus EPS estimates at $1.91, reflecting a 5.5% year-over-year increase, and revenue expectations at $6.92 billion, up 3.7%, indicating stable performance in the biopharma sector.
- Performance Outlook: Despite a double beat in the previous quarter, Gilead's 2026 non-GAAP EPS guidance midpoint of $8.65 falls below consensus, highlighting cautious market sentiment regarding its future growth potential.
- Market Analysis: Analyst Edmund Ingham notes that Gilead's heavy reliance on its HIV division, coupled with skepticism surrounding its recent $11 billion M&A spree, suggests that Q1 earnings may be underwhelming, with sluggish growth anticipated.
- Estimate Revisions: Over the past three months, EPS estimates have seen four upward revisions and five downward adjustments, while revenue estimates have experienced two upward and five downward revisions, reflecting market divergence and uncertainty regarding Gilead's future performance.
See More
Gilead Sciences to Release Q1 Earnings on May 7
- Earnings Release Announcement: Gilead Sciences is set to announce its Q1 2023 earnings on May 7, with analysts forecasting an EPS of $1.91 and revenue of $6.92 billion, reflecting a cautiously optimistic market outlook.
- Stock Performance: As of April 29, Gilead's stock closed at $136.30, indicating that investors are adopting a wait-and-see approach ahead of the earnings report, which may influence short-term market volatility.
- Market Expectation Analysis: Analysts' earnings expectations demonstrate confidence in Gilead's product pipeline and market demand, particularly in the increasingly competitive biopharmaceutical sector, where exceeding expectations could bolster the stock price.
- Financial Health Outlook: If actual results meet or exceed expectations, it could enhance investor confidence and further solidify the company's market position in the biopharmaceutical industry; conversely, disappointing results may lead to a decline in stock price.
See More
California Supreme Court to Hear Gilead Drug Liability Case
- Legal Responsibility Review: The California Supreme Court is set to hear Gilead's appeal regarding whether drug manufacturers are obligated to continue developing allegedly safer alternatives, a decision that could reshape product liability law and impact innovation in the pharmaceutical industry.
- Patient Lawsuit Background: Approximately 24,000 HIV patients have sued Gilead, alleging that the company halted the development of TAF, a drug with fewer side effects, to protect the market for TDF, potentially increasing health risks for patients.
- Debate on Innovation and Liability: In its appeal, Gilead argues that allowing patients to sue would stifle innovation, as drugmakers could face liability for failing to commercialize new drugs, which may ultimately reduce the development of new treatments.
- Profit vs. Ethical Considerations: Patients contend that Gilead made billions in additional profits from TDF after its patent expired in 2017, questioning the reasonableness of the decision to delay TAF's commercialization and highlighting the ethical responsibilities of pharmaceutical companies in balancing profit and patient health.
See More
China Emerges as a Leader in Global Pharmaceutical Innovation
- Earnings Beat: Waters reported adjusted earnings per share of $2.70, exceeding estimates of $2.31, with revenue of $1.27 billion surpassing the $1.20 billion forecast, indicating strong performance driven by the pharmaceutical segment, particularly in China.
- China's Market Growth: The pharmaceutical segment grew 14%, with China leading at over 50% growth, while India and Japan saw low-teens growth, highlighting China's rapid emergence as a key player in global pharmaceutical innovation and market expansion.
- Innovation-Driven Transformation: Despite a decline in China's generic drug market due to price restrictions, the development of innovative drugs is reshaping the landscape, with contract manufacturers rapidly scaling up to manage the entire process from discovery to development, aiming to create entities akin to Pfizer or AstraZeneca.
- Regional Performance: Asia's growth was nearly 30%, while the Americas and Europe achieved high single-digit growth, reflecting a diversified development trend in the global pharmaceutical market, with Waters' success underscoring the effectiveness of this strategic approach.
See More
Yeztugo Injection Faces Insurance Hurdles Despite Initial Uptake
- Market Acceptance: Since its June launch, Yeztugo has seen usage climb to nearly 75 patients, significantly lower than the expected 700 PrEP patients, indicating a lack of interest among patients that hampers Gilead's market expansion strategy.
- Insurance Coverage Issues: While Gilead claims over 90% of insurers cover Yeztugo, many patients face injection costs exceeding $14,000 and insurance denials, leading them to opt for cheaper daily medications, which impacts sales growth.
- Prescription Data Comparison: In the first quarter, over 9,000 prescriptions were written for Yeztugo, compared to 461,000 for Descovy, highlighting a preference for traditional daily medications that limits Yeztugo's market share.
- Future Sales Expectations: Analysts estimate that Yeztugo's annual sales could exceed $5 billion by 2032, although current insurance coverage and patient acceptance issues may hinder the achievement of this target.
See More
Analysis of Upcoming U.S. Jobs Report Outlook
- Job Market Expectations: According to FactSet consensus estimates, the U.S. is expected to add only 50,000 jobs in April, significantly lower than March's 178,000, indicating signs of economic slowdown that could impact investor confidence.
- Unemployment Rate Stability: The unemployment rate is anticipated to remain steady at 4.3%, suggesting that despite the decrease in job additions, the labor market remains relatively stable, potentially alleviating fears of an economic downturn.
- GDP Growth Situation: The U.S. GDP grew at a seasonally adjusted annualized rate of 2% in the first quarter, higher than the fourth quarter's 0.5% but below the 2.2% estimate, reflecting economic sluggishness that may influence future monetary policy decisions.
- Market Volatility: Despite a strong performance in April, with the S&P 500 and Nasdaq hitting record highs, investors should remain cautious of the upcoming
See More
